ACOG Addresses Thrombocytopenia in Pregnancy

Share this content:
ACOG Addresses Thrombocytopenia in Pregnancy
ACOG Addresses Thrombocytopenia in Pregnancy

WEDNESDAY, Aug. 24, 2016 (HealthDay News) -- Thrombocytopenia is common in pregnancy and can have causes that are serious medical disorders, with potential for maternal and fetal morbidity, according to a Practice Bulletin published in the September issue of Obstetrics & Gynecology.

Researchers from the American College of Obstetrics and Gynecology discuss thrombocytopenia in pregnancy, including definition and obstetric management.

The authors note that thrombocytopenia is frequently diagnosed by obstetricians in pregnant women as platelet counts are included as part of routine prenatal screening. Thrombocytopenia is defined as a platelet count of less than 150 × 109/L and is seen in 7 to 12 percent of pregnancies. Various physiologic or pathologic conditions can cause thrombocytopenia, including some that are unique to pregnancy, such as hypertension in pregnancy. Other causes include primary and secondary immune thrombocytopenia, association with systemic conditions, and congenital thrombocytopenia. Some causes are serious medical conditions, which could potentially cause maternal and fetal morbidity. Other conditions, such as gestational thrombocytopenia are benign, with no maternal or fetal risks. Controversies surround obstetric management of the condition due to the increased recognition of maternal and fetal thrombocytopenia.

"Clinicians must weigh the risks of maternal and fetal bleeding complications against the costs and morbidity of diagnostic tests and invasive interventions," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »